A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis

BACKGROUND & AIMS: Primary sclerosing cholangitis (PSC) is a rare, cholestatic liver disease with no currently approved therapies. Obeticholic acid (OCA) is a potent farnesoid X receptor (FXR) agonist approved for the treatment of primary biliary cholangitis. We investigated the efficacy and saf...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Hepatol
Main Authors: Kowdley, Kris V., Vuppalanchi, Raj, Levy, Cynthia, Floreani, Annarosa, Andreone, Pietro, LaRusso, Nicholas F., Shrestha, Roshan, Trotter, James, Goldberg, David, Rushbrook, Simon, Hirschfield, Gideon M., Schiano, Thomas, jin, Yuying, Pencek, Richard, MacConell, Leigh, Shapiro, David, Bowlus, Christopher L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8157171/
https://ncbi.nlm.nih.gov/pubmed/32165251
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhep.2020.02.033
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados